Isotechnika Inc. has been issued U.S. Patent No. 7,060,672 for its lead immunosuppressive drug, ISA247.
The patent entitled "Novel Cyclosporin Analog Formulations" is the first patent to be issued in this patent family in the United States with patent claims filed in a total of 36 countries.
"Our patent position with ISA247 continues to be strengthened. A total of 20 patents have been issued relating to ISA247's composition, formulation and synthetic methods," stated Dr. Randall Yatscoff, Isotechnika's President and Chief Executive Officer.
"Our patent team will continue to pursue additional claims for ISA247 where appropriate to ensure that our intellectual property is well protected in all jurisdictions."
The Edmonton, Alberta, Canada-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments.
Comment Preview